Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | HBB | P68871 | 1/20 | 0.41 |
| ▸ | TYMS | P04818 | 1/20 | 0.41 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.40 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.40 |
| ▸ | NT5E | P21589 | 1/20 | 0.40 |
| ▸ | TK1 | P04183 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12595726 | 0.83 | LMNA (0.65) | LMNASMN1; SMN2MAPTESR1TSHR | |
| SCHEMBL4277166 | 0.80 | LMNA (0.70) | LMNASMN1; SMN2TYMSTK1 | |
| SCHEMBL9856524 | 0.80 | LMNA (0.57) | LMNASMN1; SMN2MAPTESR1TYMS | |
| SCHEMBL4277164 | 0.80 | LMNA (0.70) | LMNASMN1; SMN2TYMSTK1 | |
| SCHEMBL570200 | 0.78 | LMNA (0.55) | LMNASMN1; SMN2MAPTESR1TYMS | |
| SCHEMBL8329362 | 0.78 | LMNA (0.55) | LMNASMN1; SMN2MAPTESR1TYMS | |
| SCHEMBL8329365 | 0.77 | LMNA (0.44) | LMNASMN1; SMN2MAPTESR1TSHR | |
| SCHEMBL4276828 | 0.74 | LMNA (0.51) | LMNASMN1; SMN2MAPTTSHRPMP22 | |
| SCHEMBL25061415 | 0.73 | TK1 (0.47) | TK1 | |
| SCHEMBL9098319 | 0.73 | TYMS (0.53) | LMNASMN1; SMN2TYMSTK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120309705-A1 | NOVEL 3'-DEOXY-3'-METHYLIDENE-BETA-L-NUCLEOSIDES | NOVADEX PHARMACEUTICALS AB (SE) | 2012-12-06 | — | — | US | disclosed |
| WO-2011075052-A1 | NOVEL 3´-DEOXY-3´-METHYLIDENE- -L-NUCLEOSIDES | NOVADEX PHARMACEUTICALS AB (SE) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309705-A1 | NOVEL 3'-DEOXY-3'-METHYLIDENE-BETA-L-NUCLEOSIDES | ENTPD5, MTAP, SLC29A1 | LMNA 262/4885SMN1; SMN2 3178/4885MAPT 3753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.